Ainos, Inc. (NASDAQ:AIMD) Short Interest Down 37.6% in October

Ainos, Inc. (NASDAQ:AIMD) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 238,800 shares, a decline of 37.6% from the September 30th total of 382,500 shares. Approximately 16.4% of the shares of the stock are sold short. Based on an average trading volume of 676,300 shares, the short-interest ratio is presently 0.4 days.

Ainos Stock Performance

Shares of Ainos stock opened at $0.56 on Friday. The business has a 50-day moving average price of $0.55 and a 200-day moving average price of $0.76. Ainos has a twelve month low of $0.45 and a twelve month high of $4.29. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.45 and a current ratio of 1.48.

Ainos (NASDAQ:AIMD) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter. Ainos had a negative return on equity of 64.54% and a negative net margin of 15,348.14%.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.